Across TCGA pan-cancer cohorts, AKR1B10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKR1B10 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AKR1B10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AKR1B10 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where AKR1B10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.526	0.296	<.001	109	view →
LUAD	OS	Median	II,III,IV	0.427	0.842	<.001	57	view →
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	10	view →
GBM	OS	Median	All	0.373	0.664	.017	3	view →
UCEC	OS	Median	All	0.984	0.916	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AKR1B10 tumor-vs-normal RNA expression · all AKR1B10 data types